Lead Dosing Session Monitor
$124,800,000–$145,600,000 year
On-siteDallas, Texas, United States
Job Summary
Lead study therapist in psychedelic clinical trials for depression, anxiety, and mood disorders. Provide support to participants throughout the clinical trial in alignment with the study protocol and training guidelines. Collaborate with clinicians and site staff managing participant participation. Conduct pre-dose preparation, real-time monitoring during dosing sessions, and post-dose follow-up. Complete study-sponsored and site-specific training. Perform administrative tasks and adhere to ICH-GCP standards. This per diem, as-needed role requires approximately 2-3 days per week of direct participant-facing responsibilities with flexibility for shifting schedules. A majority of appointments are in person at Watertown, Boston, Harlem, or Bronx locations, with remote options available.
Required Qualifications
- Licensed mental health professional in Massachusetts, New York, Pennsylvania, or Texas (e.g., PsyD, PhD, LCSW, LMSW, LMHC, LMFT)
- Ability to provide psychotherapy in compliance with state regulations
- Attention to detail
- Strict adherence to ICH-GCP standards
- Adherence to protocol requirements
- Experience working with individuals with depression, anxiety, or other mood disorders
- Strong interpersonal and communication skills
- Interest in advancing mental health care in a clinical research setting
- Ability to meet fixed scheduling expectations
- Consistent on-site availability
- Willingness to learn and adhere to ICH-GCP standards
- Willingness to travel between regional sites
- Final candidate must be approved by both Adams Clinical and the study sponsor
- Must provide documentation verifying their identity and authorization to work in the United States
- Must complete Form I-9 within the required timeframe
Desired Qualifications
- Willingness to travel between regional sites (Watertown and Boston; Harlem and Bronx)
Hiring someone like this?
Get your role in front of qualified candidates on Sorce.